Staphylococcus Aureus Infection Clinical Trial
Official title:
A Phase Ia Single-center, Randomized, Double-blind, Placebo Controlled, Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults Aged 18-65 Years in China
Verified date | October 2017 |
Source | Jiangsu Province Centers for Disease Control and Prevention |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Before this study, there will be an open-label, dose-escalation pilot study with a total of
30 participants with 10 per dosage group. The aim of the pilot study is to explore the
preliminary safety of an experimental recombinant staphylococcus aureus vaccine.
This is a single center, double-blind, placebo control, dose-escalation phase 1 clinical
trial. This study will determine the safety and side-effect profile, and immunogenicity of an
experimental recombinant staphylococcus aureus vaccine. The study will be carried out
following a dose-escalation method from the low dosage to the high dosage, i.e. the higher
dosage vaccine could only be administrated after the first seven-day safety of the lower
dosage vaccine is confirmed after safety observation.
Status | Completed |
Enrollment | 144 |
Est. completion date | September 2017 |
Est. primary completion date | July 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Healthy volunteers aged 18 to 65 years (aged over 18 and under 66 years). - Able to comply with all clinical trial protocol requirements and willing to complete all the visit plan process during the whole clinical trial observation period. - Able to understand the content of informed consent and willing to sign the informed consent. - Able to complete the diary card independently. - For females only (18-49 years), a negative urine pregnancy test and willing to practice continuous effective contraception during the study. - Axillary temperature =37.0°C. Exclusion Criteria: First Immunization exclusion standard: - Prior receipt of Staphylococcus aureus vaccine - Any confirmed Staphylococcus aureus infection disease in the past 12 month. - History of asthma, hereditary angioneurotic edema, diabetes, malignancy or other serious disease. Participation in the clinical trial is likely to increase the disease risk and interfere with the observation of clinical trial index. - Prior blood donation or Blood loss over 400ml in the last 3 months; - Coagulation disorders (coagulation factor deficiency, coagulopathy or platelet disorder) diagnosed by doctors, or obvious bruises or blood coagulation noticed. - History of allergic disease likely to be exacerbated by any component of the vaccine, including allergy, urticaria, respiratory difficulty, angioneurotic edema or abdominal pain. - Any autoimmune disease or immunodeficient state, parents, brother and sister with autoimmune disease or immunodeficient disease. - Taking immunoglobulins and/or any blood products within the last 12 months. - Asplenia, functional asplenia or asplenia caused by any situation or splenectomy. - Any acute disease or acute attack of chronic disease in last 7 days. - History of thyroidectomy or thyroid disease requiring treatment in the last 12 months. - Immunosuppressor, cytotoxic therapy, inhaled corticosteroid (excluding corticosteroids spray treatment of allergic rhinitis, acute and non-concurrent corticosteroids treatment) - Participation in another research study involving receipt of an investigational product in the last 30 days. - Woman who is breast-feeding. - Prior administration of attenuated vaccine in last 28 days. - Prior administration of subunit vaccine, inactivated vaccine or allergic therapy in last 14 days. - Current anti-tuberculosis prophylaxis or therapy - Any other conditions may compromise the safety or availability of participants in the judgment of the investigator. Following Immunization exclusion standard: - Any grade 3 or more serious adverse reaction happen since the last vaccination. - Other condition violates the inclusion criteria or meets the exclusion criteria is noticed after the first immunization. - Acute or chronic infections at the vaccination day (axillary temperature>37.0°C). - According to the investigator, the participant should not continue participating in the study. |
Country | Name | City | State |
---|---|---|---|
China | Xiaokui Hu | Taixing | Jiangsu |
Lead Sponsor | Collaborator |
---|---|
Jiangsu Province Centers for Disease Control and Prevention | Chengdu Olymvax Biopharmaceuticals Inc., Third Military Medical University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Changes of the colonization of Staphylococcus aureus on nasal mucosus after vaccination. | Changes of the colonization of Staphylococcus aureus on nasal mucosus after vaccination with the Staphylococcus aureus vaccine at day at day 3, 7, 10, 14, 17, 21, 42 and month 3, 6. | within 6 months after the vaccination | |
Other | Specific functional antibody responses to the Staphylococcus aureus vaccine | Specific functional antibody responses to the Staphylococcus aureus vaccine at day 7, 14, 21, 42 and month 3, 6. | within 6 months after the vaccination | |
Other | Specific T cell immune responses to the Staphylococcus aureus vaccine. | Specific T cell immune responses to the Staphylococcus aureus vaccine at day at day7, 14, 21, 42 and month 3, 6 measured by ELISpot. | within 6 months after the vaccination | |
Primary | Occurrence of injection site adverse reactions after vaccination | Occurrence of solicited injection site adverse reactions within 21 days after vaccination with the Recombinant Staphylococcus aureus vaccine | within 21 days after the vaccination | |
Primary | Occurrence of systematic adverse reactions after vaccination | Occurrence of solicited systematic adverse reactions within 21 days after vaccination with the Recombinant Staphylococcus aureus vaccine | within 21 days after the vaccination | |
Secondary | Occurrence of unsolicited adverse reactions after vaccination. | Occurrence of unsolicited adverse reactions within 42 days after vaccination with the Recombinant Staphylococcus aureus vaccine | within 42 days after the vaccination | |
Secondary | Occurrence of serious adverse events after the vaccination. | Occurrence of serious adverse events within 6 months after the vaccination with the Recombinant Staphylococcus aureus vaccine | within 6 months after the vaccination | |
Secondary | Changes of the blood routine after vaccination. | Changes of the blood routine after vaccination with the Recombinant Staphylococcus aureus vaccine on day 3, 7, 10, 14 and 17. | day 0-17 after the vaccination | |
Secondary | Changes of the blood biochemistry after vaccination. | Changes of the blood biochemistry after vaccination with the Recombinant Staphylococcus aureus vaccine on day 3, 7, 10, 14 and 17. | day 0-17 after the vaccination | |
Secondary | Geometric mean titre against specific antigens | Geometric mean titre measured at day 0, 7, 14, 21, 42 and month 3, 6. | within 6 months after the vaccination | |
Secondary | Geometric mean fold increase against specific antigens | Geometric mean fold increase measured at day 7, 14, 21, 42 and month 3, 6. | within 6 months after the vaccination | |
Secondary | Positive conversion rate of serum against specific antigens | Positive conversion rate of serum measured at day 7, 14, 21, 42 and month 3, 6. | within 6 months after the vaccination |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04210505 -
Nasal Decolonization of Dialysis Patients Noses
|
Phase 4 | |
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Completed |
NCT02282605 -
Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects
|
Phase 1/Phase 2 | |
Recruiting |
NCT06319235 -
Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®
|
Phase 1/Phase 2 | |
Enrolling by invitation |
NCT06317688 -
Effectiveness of Highly Purified Anhydrous (HPA) Lanolin Versus Extra-Virgin Coconut Oil in Preventing Subacute Lactation Mastitis
|
Phase 1 | |
Withdrawn |
NCT02741869 -
Photodisinfection for the Decolonization of Staphylococcus Aureus in Hemodialysis Patients
|
N/A | |
Completed |
NCT03966040 -
A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults
|
Phase 1 | |
Completed |
NCT04803708 -
Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers
|
Phase 1/Phase 2 | |
Recruiting |
NCT05117398 -
Dalbavancin Versus Standard Antibiotic Therapy for Catheter-related Bloodstream Infections Due to Staphylococcus Aureus
|
Phase 3 | |
Not yet recruiting |
NCT06456424 -
Bacteriophage Therapy for Methicillin-Sensitive Staphylococcus Aureus Prosthetic Joint Infection
|
Phase 1/Phase 2 | |
Completed |
NCT02820883 -
A Study of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults
|
Phase 0 | |
Active, not recruiting |
NCT01879761 -
Immune Resolution After Staphylococcus Aureus Bacteremia
|
||
Completed |
NCT01375621 -
Livestock Contact and MRSA in Rural Areas
|
||
Recruiting |
NCT00532324 -
Community-Acquired Methicillin Resistant Staphylococcus Aureus Colonization in Pregnant Women and Infections in Newborns
|
N/A | |
Completed |
NCT04503252 -
Probability of Target Attainment With Standard Intermittent Bolus Administration of Cefazolin in Patients With Complicated Infections Caused by Staphylococcus Aureus
|
||
Recruiting |
NCT06368856 -
Pharmacology of Mupirocin in Nasal Application in Healthy Volunteers: Monocentric Study
|
Phase 1 | |
Not yet recruiting |
NCT05899140 -
Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial
|
Phase 4 | |
Completed |
NCT01792804 -
Staphylococcus Aureus Bacteremia Antibiotic Treatment Options
|
Phase 3 | |
Enrolling by invitation |
NCT04897971 -
Serum Based Diagnosis of and Monitoring of Infection Recovery in Orthopedic Spine Implant Infections
|
||
Completed |
NCT00572910 -
A Study to Evaluate the Safety and Immunogenicity of V710 in Adults With Kidney Disease on Hemodialysis (V710-005)(COMPLETED)
|
Phase 2 |